Human CD40L Monoclonal Antibody | anti-CD40L antibody

Human Anti-CD40L (CD40 Ligand, CD154, Tumor Necrosis Factor Ligand Superfamily Member 5, TNFSF5, Gp39, TRAP)

Cat. Num. AAA6120622

• Reactivity: Canine, human
• Applications: Flow Cytometry, Western Blot
• Purity: Purified by Protein A affinity chromatography.
• Synonyms: CD40L; Monoclonal Antibody; Human Anti-CD40L (CD40 Ligand; CD154; Tumor Necrosis Factor Ligand Superfamily Member 5; TNFSF5; Gp39; TRAP); anti-CD40L antibody

• Host: Human
• Reactivity: Canine, human
• Clonality: Monoclonal
• Isotype: IgG1, k
• Clone Number: hu5c8
• Specificity: Recognizes and binds human CD40L with an IC50 of 0.845ug/ml. Species Crossreactivity: canine
• Purity/Purification: Purified by Protein A affinity chromatography.
• Form/Format: Supplied as a liquid in PBS. No preservative added.
• Concentration: 1mg/mL (varies by lot)

• Applicable Applications for anti-CD40L antibody: Flow Cytometry (FC), Western Blot (WB)
• Application Notes: Flow Cytometry: 1ug/ml; Western Blot: 1ug/ml; Blocking: Neutralizes CD40L function by blocking the interaction between CD40 and CD40L in vitro and in vivo.; Optimal dilutions to be determined by the researcher.
• Endotoxin: <0.001EU/ug
• Immunogen: Recombinant protein corresponding to human CD40L.
• Note: Preservative Free
• Preparation and Storage: May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Related Product Information for anti-CD40L antibody

CD40 Ligand (CD40L), renamed TNFSF5 but now also known as CD154, TRAP and gp39, is a 34-39kD type II transmembrane glycoprotein, that belongs to the TNF superfamily, and a surface receptor expressed on activated T cells which acts as a costimulatory molecule to trigger immune responses. CD40L binds to CD40, which is essential in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development and germinal center formation. CD40 is constitutively expressed by antigen presenting cells, including dendritic cells, B cells and macrophages. Consistent with its widespread expression on normal cells, CD40 is also expressed on a wide range of tumor cells. CD40L levels are increased in serum and in inflamed tissues of patients with autoimmune diseases.

References

1. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys: J.V Gobburu, et al.; JPET 286, 925 (1998). 2. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates: A.D. Kirk, et al.; Nat. Med. 5, 686 (1999). 3. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154: N.S. Kenyon, et al.; PNAS 96, 8132 (1999). 4. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154: N.S. Kenyon, et al.; Diabetes 48, 1473 (1999). 5. Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody: R.N. Pierson, et al.; Transplantation 68, 1800 (1999). 6. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody: M. Kar- pusas, et al.; Structure 9, 321 (2001). 7. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimu- latory molecule blockade in rhesus renal allograft recipients: C.S. Cho, et al.; Transplantation 72, 587 (2001). 8. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates: E.A. Elster, et al.; Transplantation 72, 1473 (2001). 9. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus: W. Huang, et al.; Arthr. Rheum. 46, 1554 (2002). 10. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates: H. Xu, et al.; Transplantation 74, 940 (2002). 11. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis: D.T. Boumpas, et al.; Arthr. Rheum. 48, 719 (2003). 12. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154- CD40 interactions: A.C. Grammer, et al.; J. Clin. Invest. 112, 1506 (2003). 13. Human CD34(+) blood cells induce T-cell unresponsiveness to specific alloantigens only under costimulatory blockade: M. Arpinati, et al.; Exp. Hematol. 31, 31 (2003). 14. CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation: C. Jochum, et al.; Biol. Blood Marrow. Transplant. 13, 164 (2007). 15. Enhancement of T cell activation by immobilized hu5C8 (anti-CD40L) monoclonal antibody: M. Arpinati, et al.; Eur. J. Haematol. 80, 322 (2008). 16. Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig: S.S. Graves, et al.; Transplantation 88, 317 (2009).